Literature DB >> 6413411

Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.

G Döring, N Høiby.   

Abstract

During a 10-year period, the clinical states of 10 cystic fibrosis patients were evaluated on the basis of monthly measurement of lung function and weight; serum antibody titers to alkaline protease and elastase and the number of precipitins to Pseudomonas aeruginosa standard antigen were determined by radioimmunoassay and crossed immunoelectrophoresis. Alkaline protease and elastase concentrations of the P. aeruginosa strains from the patients were measured in vitro. The immune response increased in nearly all patients after the onset of chronic P. aeruginosa lung infection over years, suggesting unimpaired production of these antigens during P. aeruginosa lung infection, whereas the clinical states declined. The mean time for immune response was 15 months for alkaline protease, 11 months for elastase, and 6 months for standard antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413411      PMCID: PMC264542          DOI: 10.1128/iai.42.1.197-201.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  The penetration of antibiotics through sodium alginate and through the exopolysaccharide of a mucoid strain of Pseudomonas aeruginosa.

Authors:  M P Slack; W W Nichols
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

2.  [Extracellular toxins of Pseudomonas aeruginosa. II. Effect of two proteases on human immunoglobulins IgG, IgA and secretory IgA (author's transl)].

Authors:  G Döring; H J Obernesser; K Botzenhart
Journal:  Zentralbl Bakteriol A       Date:  1981-03

3.  Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections.

Authors:  M I Marks; R Prentice; R Swarson; E K Cotton; T C Eickhoff
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

4.  Incidence of mucoid Pseudomonas aeruginosa from clinical sources.

Authors:  R G Doggett
Journal:  Appl Microbiol       Date:  1969-11

5.  Pseudomonas colonization in cystic fibrosis. A study of 160 patients.

Authors:  L L Kulczycki; T M Murphy; J A Bellanti
Journal:  JAMA       Date:  1978-07-07       Impact factor: 56.272

6.  A new polysaccharide resembling alginic acid isolated from pseudomonads.

Authors:  A Linker; R S Jones
Journal:  J Biol Chem       Date:  1966-08-25       Impact factor: 5.157

7.  Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases.

Authors:  L Gray; A Kreger
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

8.  Hypogammaglobulinemia in patients with cystic fibrosis.

Authors:  W J Matthews; M Williams; B Oliphint; R Geha; H R Colten
Journal:  N Engl J Med       Date:  1980-01-31       Impact factor: 91.245

9.  Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats.

Authors:  D E Woods; S J Cryz; R L Friedman; B H Iglewski
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

10.  Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis.

Authors:  J Lam; R Chan; K Lam; J W Costerton
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

View more
  42 in total

Review 1.  Cystic fibrosis: yesterday, today and tomorrow.

Authors:  R Dinwiddie
Journal:  J R Soc Med       Date:  1991       Impact factor: 5.344

2.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

3.  Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1986-11       Impact factor: 3.791

4.  Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Authors:  P E Makidon; J Knowlton; J V Groom; L P Blanco; J J LiPuma; A U Bielinska; J R Baker
Journal:  Med Microbiol Immunol       Date:  2009-12-06       Impact factor: 3.402

Review 5.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

6.  Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection.

Authors:  H K Johansen; F Espersen; S J Cryz; H P Hougen; A Fomsgaard; J Rygaard; N Høiby
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

Review 7.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

8.  Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection.

Authors:  Fadie T Coleman; Simone Mueschenborn; Gloria Meluleni; Christopher Ray; Vincent J Carey; Sara O Vargas; Carolyn L Cannon; Frederick M Ausubel; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

10.  Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori.

Authors:  H K Johansen; A Nørgaard; L P Andersen; P Jensen; H Nielsen; N Høiby
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.